Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Gross Margin: 2017-2025

Historic Gross Margin for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to 77.65%.

  • Puma Biotechnology's Gross Margin rose 1378.00% to 77.65% in Q3 2025 from the same period last year, while for Sep 2025 it was 76.91%, marking a year-over-year increase of 762.00%. This contributed to the annual value of 72.06% for FY2024, which is 134.00% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Gross Margin is 77.65%, which was up 1.45% from 76.54% recorded in Q2 2025.
  • Puma Biotechnology's Gross Margin's 5-year high stood at 80.79% during Q4 2022, with a 5-year trough of 63.87% in Q3 2024.
  • Moreover, its 3-year median value for Gross Margin was 76.44% (2024), whereas its average is 74.57%.
  • Per our database at Business Quant, Puma Biotechnology's Gross Margin slumped by 1,449bps in 2023 and then surged by 1,378bps in 2025.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Gross Margin stood at 78.51% in 2021, then soared by 228bps to 80.79% in 2022, then slumped by 1,449bps to 66.30% in 2023, then soared by 1,013bps to 76.44% in 2024, then skyrocketed by 1,378bps to 77.65% in 2025.
  • Its Gross Margin stands at 77.65% for Q3 2025, versus 76.54% for Q2 2025 and 77.06% for Q1 2025.